DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the specialty pharmaceutical ...

Durect (DRRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

CUPERTINO, CA - DURECT Corporation, a biopharmaceutical company with a market capitalization of $24.21 million, has been notified by the Nasdaq Stock Market of non-compliance with its minimum bid ...

CUPERTINO, CA - DURECT Corporation, a biopharmaceutical company with a market capitalization of $24.21 million, has been notified by the Nasdaq Stock Market of non-compliance with its minimum bid ...

The Health Foundation of South Florida, the region's largest philanthropic organization dedicated to improving community ...